To investigate the safety and effectiveness about administration of both donepezil hydrochloride and menatine hydrochloride in patients with Alzheimer's Disease in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
3,482
Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Unnamed facility
Multiple Locations, Japan
Investigations on adverse events and adverse drug reactions
Time frame: Up to 12 months
Severity of dementia based on the Functional Assessment Staging Test (FAST)
FAST is a seven stage system based on level of functioning and daily activities. It focuses more on an individual's level of functioning and activities of daily living versus cognitive decline
Time frame: Baseline, Month 3, Month 6, and Month 12
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
The MMSE is a brief 30-point questionnaire test that is used for the assessment of dementia patients' cognitive impairment. Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment. Lower scores indicate worsening.
Time frame: Baseline and Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.